End-of-day quote
Korea S.E.
23:00:00 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
10,540
KRW
|
+0.48%
|
|
+4.46%
|
-7.87%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
5,736,545
|
3,074,925
|
1,399,655
|
1,289,542
|
-
|
Enterprise Value (EV)
2 |
4,532
|
1,154
|
1,400
|
1,448
|
1,482
|
P/E ratio
|
5.16
x
|
3.46
x
|
-2.71
x
|
-27
x
|
-34.7
x
|
Yield
|
2.26%
|
6.49%
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.96
x
|
1.05
x
|
2.13
x
|
1.82
x
|
1.63
x
|
EV / Revenue
|
1.55
x
|
0.39
x
|
2.13
x
|
2.05
x
|
1.87
x
|
EV / EBITDA
|
3.26
x
|
0.97
x
|
-
|
21.3
x
|
18.5
x
|
EV / FCF
|
4.34
x
|
1.96
x
|
-
|
-36.4
x
|
-38.2
x
|
FCF Yield
|
23.1%
|
51%
|
-
|
-2.75%
|
-2.62%
|
Price to Book
|
2.58
x
|
1.07
x
|
-
|
1.6
x
|
1.59
x
|
Nbr of stocks (in thousands)
|
102,622
|
101,988
|
122,347
|
122,347
|
-
|
Reference price
3 |
55,900
|
30,150
|
11,440
|
10,540
|
10,540
|
Announcement Date
|
25/02/22
|
09/03/23
|
28/02/24
|
-
|
-
|
1KRW in Million2KRW in Billions3KRW Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
2,931
|
2,928
|
655.7
|
707.3
|
793.5
|
EBITDA
1 |
-
|
1,389
|
1,187
|
-
|
68
|
80.2
|
EBIT
1 |
-
|
1,370
|
1,147
|
-248.1
|
-46.8
|
-33.3
|
Operating Margin
|
-
|
46.73%
|
39.16%
|
-37.83%
|
-6.62%
|
-4.2%
|
Earnings before Tax (EBT)
1 |
-
|
1,444
|
1,242
|
-438.6
|
-64.3
|
-50
|
Net income
1 |
615.6
|
1,066
|
883.4
|
-467.7
|
-48.7
|
-37.9
|
Net margin
|
-
|
36.36%
|
30.17%
|
-71.33%
|
-6.89%
|
-4.78%
|
EPS
2 |
6,583
|
10,824
|
8,721
|
-4,219
|
-391.0
|
-304.0
|
Free Cash Flow
3 |
-
|
1,044,892
|
588,234
|
-
|
-39,800
|
-38,800
|
FCF margin
|
-
|
35,644.57%
|
20,087.21%
|
-
|
-5,627.03%
|
-4,889.73%
|
FCF Conversion (EBITDA)
|
-
|
75,230.03%
|
49,537.81%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
98,027.29%
|
66,585.09%
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
1,266
|
1,957
|
-
|
-
|
-
|
Announcement Date
|
14/05/21
|
25/02/22
|
09/03/23
|
28/02/24
|
-
|
-
|
1KRW in Billions2KRW3KRW in Million Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
---|
Net sales
1 |
526.7
|
443.8
|
1,388
|
795
|
551.2
|
193.8
|
182.4
|
162.6
|
151
|
159.6
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-9.591
|
-
|
EBIT
1 |
249.5
|
147.9
|
619.6
|
348.1
|
293.4
|
-114.6
|
-123.8
|
-76.41
|
-44.24
|
-29.61
|
Operating Margin
|
47.37%
|
33.32%
|
44.63%
|
43.79%
|
53.24%
|
-59.13%
|
-67.86%
|
-46.98%
|
-29.29%
|
-18.55%
|
Earnings before Tax (EBT)
|
-
|
156
|
648.7
|
466.9
|
487.4
|
-361
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
130.5
|
474.5
|
340
|
421.3
|
-352.4
|
-
|
-82.49
|
-64.12
|
-98.43
|
Net margin
|
-
|
29.4%
|
34.17%
|
42.77%
|
76.44%
|
-181.84%
|
-
|
-50.72%
|
-42.45%
|
-61.67%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
25/02/22
|
12/05/22
|
03/08/22
|
03/11/22
|
09/03/23
|
15/05/23
|
11/08/23
|
13/11/23
|
28/02/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
159
|
193
|
Net Cash position
1 |
-
|
1,205
|
1,921
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
2.334
x
|
2.401
x
|
Free Cash Flow
2 |
-
|
1,044,892
|
588,234
|
-
|
-39,800
|
-38,800
|
ROE (net income / shareholders' equity)
|
-
|
72%
|
34.2%
|
-15.6%
|
-1.8%
|
-1.4%
|
ROA (Net income/ Total Assets)
|
-
|
47.7%
|
29%
|
-
|
-1.3%
|
-1%
|
Assets
1 |
-
|
2,236
|
3,051
|
-
|
3,746
|
3,790
|
Book Value Per Share
3 |
-
|
21,658
|
28,207
|
-
|
6,603
|
6,648
|
Cash Flow per Share
|
-
|
12,554
|
8,788
|
-
|
-
|
-
|
Capex
1 |
-
|
190
|
302
|
-
|
55.5
|
67.5
|
Capex / Sales
|
-
|
6.48%
|
10.31%
|
-
|
7.85%
|
8.51%
|
Announcement Date
|
14/05/21
|
25/02/22
|
09/03/23
|
28/02/24
|
-
|
-
|
1KRW in Billions2KRW in Million3KRW Last Close Price
10,540
KRW Average target price
10,000
KRW Spread / Average Target -5.12% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.87% | 952M | | -1.89% | 12.56B | | -9.59% | 7.68B | | -1.31% | 5.29B | | +21.82% | 5.24B | | +0.02% | 4.57B | | -50.89% | 3.29B | | +6.42% | 2.6B | | -10.02% | 2.2B | | -8.29% | 1.79B |
Diagnostic & Testing Substances
|